Upheal
AI NativeThe first smart platform for mental health clinicians.
Est 2021|Valuation $48.5M|Raised $14.3M
The first smart platform for mental health clinicians.
Published Jul 14, 2026
| Starting Price | Published individual-tier free listing (vendor listing) | Entry-tier published pricing (vendor listing) | Published comparisons indicate a mid-range starting price; verify on vendor sites |
| Typical Fit | Clinicians seeking automated documentation with telehealth capture and session analytics | Clinicians/practices wanting defined note quotas and extensive template support | Practices prioritizing measurement-based care and assessment integration |
| Key Strength | Automated note generation, session analytics, and privacy controls emphasized by vendor | Explicit tiered note counts and broad template coverage at higher tiers | Assessment and measurement integration positioning |
| Key Weakness | Reported diarization issues and multi-participant limitations; Team pricing not publicly detailed | Cost can scale at higher volumes; fair-use or quota limits affect economics | Fewer analytics features compared to tools focused on session analytics |
—
Upheal’s vendor-produced comparisons emphasize privacy posture, template customization, and telehealth-based workflows. Because these comparisons are vendor-produced, procurement teams should validate comparative claims through independent trials and peer references.
On pricing transparency, some competitors publish explicit note counts and tier limits, while Upheal’s public individual plans currently list unlimited notes for individuals; procurement should confirm whether this applies in practice and for which modalities.
Community and forum commentary indicates that price and simplicity are important factors for many clinicians; some clinicians may prefer more basic, lower-cost solutions if advanced analytics are not required.